Pharmaceuticals company Zydus Lifesciences announced Q3FY25 results Revenue from operations at Rs 52,691 million, up 17% over Q3FY24. Research & Development (R&D;) investments for Q3FY25 stood at Rs 5,031 million (9.5% of revenues). EBITDA for Q3FY25 was Rs 13,876 million, up 26% YoY. EBITDA margin for Q3FY25 stood at 26.3%, which is an improvement of 180 bps on a YoY basis. Net Profit for Q3FY25 was Rs 10,235 million, up 30% YoY. Capex (organic) for Q3FY25 was Rs 2,907 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said: We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations. Result PDF
Pharmaceuticals company Zydus Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations at Rs 52,370 million, up 20% over Q2FY24. Research & Development (R&D;) investments for the Q2FY25 stood at Rs 4,800 million (9.2% of revenues). EBITDA for the quarter was Rs 14,614 million, up 28% YoY. EBITDA margin for the quarter stood at 27.9% which is an improvement of 170 bps on a YoY basis. Net Profit for the Q2FY25 was Rs 9,112 million, up 14% YoY. Capex (organic) for the quarter was Rs 3,017 million. H1FY25 Financial Highlights: Revenue from operations at Rs 114,445 million, up 20% over H1FY24. Research & Development (R&D;) investments stood at Rs 8,725 million (7.6% of revenues). EBITDA was Rs 35,454 million, up 34% YoY. EBITDA margin stood at 31%, which is an improvement of 310 bps over H1FY24. Net Profit was Rs 23,311 million, up 24% YoY. Capex (organic) for the half year was Rs 6,031 million. Net Debt to Equity ratio as on 30th September, 2024 was -0.12x while Net Debt to EBITDA stood at -0.41x at the end of H1FY25. Net Cash (negative Net Debt) as on H1FY25 was Rs 25,906 million. Sharvil Patel, Managing Director - Zydus Lifesciences, said: Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core. Result PDF
Pharmaceuticals company Zydus Lifesciences announced Q1FY25 results: Total revenues grew 21% YoY to Rs 62,075 million, led by growth across businesses. India branded formulations business posted double-digit growth and outpaced the market growth both in the chronic and acute segments. Consumer Wellness business delivered an industry leading double-digit growth aided by improved demand scenario and extended summer. US formulations business registered a robust sequential and y-o-y growth driven by new launches and volume expansion in base portfolio. On the international markets front, demand scenario remained strong across key markets and drove the growth. EBITDA margin stood at 33.6%, up 430 bps YoY. Capex (organic) for the quarter: Rs 3,014 million. Net cash: Rs 18,922 million (at 30-Jun’24) vs 8,561 million (at 31-Mar’24) Result PDF